Ironwood Pharmaceuticals, Inc.

Symbol: IRWD

NASDAQ

6.74

USD

Market price today

  • -1.0492

    P/E Ratio

  • 0.1032

    PEG Ratio

  • 1.07B

    MRK Cap

  • 0.00%

    DIV Yield

Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

1.00%

Operating Profit Margin

-2.12%

Net Profit Margin

-2.26%

Return on Assets

-2.13%

Return on Equity

12.85%

Return on Capital Employed

-4.81%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Thomas A. McCourt
Full-time employees:267
City:Boston
Address:100 Summer Street
IPO:2010-02-03
CIK:0001446847

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.996% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.120%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -2.264%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -2.128% return, is a testament to Ironwood Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Ironwood Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 12.853%. Furthermore, the proficiency of Ironwood Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -4.814% return on capital employed.

Stock Prices

Ironwood Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8.43, while its low point bottomed out at $7.71. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Ironwood Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing IRWD liquidity ratios reveals its financial health of the firm. The current ratio of 84.49% gauges short-term asset coverage for liabilities. The quick ratio (80.14%) assesses immediate liquidity, while the cash ratio (33.38%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio84.49%
Quick Ratio80.14%
Cash Ratio33.38%

Profitability Ratios

IRWD profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -214.14% underscores its earnings before tax deductions. The effective tax rate stands at -8.81%, revealing its tax efficiency. The net income per EBT, 105.71%, and the EBT per EBIT, 101.01%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -212.00%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-214.14%
Effective Tax Rate-8.81%
Net Income per EBT105.71%
EBT per EBIT101.01%
EBIT per Revenue-212.00%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.84, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding80
Operating Cycle106.45
Days of Payables Outstanding1815
Cash Conversion Cycle-1708
Receivables Turnover3.43
Payables Turnover0.20
Inventory Turnover1575000.00
Fixed Asset Turnover24.36
Asset Turnover0.94

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.18, and free cash flow per share, 1.17, depict cash generation on a per-share basis. The cash per share value, 0.59, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.41, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.18
Free Cash Flow per Share1.17
Cash per Share0.59
Operating Cash Flow Sales Ratio0.41
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio0.26
Short Term Coverage Ratio0.90
Capital Expenditure Coverage Ratio671.89
Dividend Paid and Capex Coverage Ratio671.89

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 148.81%, highlights its total liabilities relative to assets. With a debt-equity ratio of -2.02, we discern the balance between debt and equity financing. The long-term debt to capitalization, 327.80%, and total debt to capitalization, 197.63%, ratios shed light on its capital structure. An interest coverage of -43.40 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio148.81%
Debt Equity Ratio-2.02
Long Term Debt to Capitalization327.80%
Total Debt to Capitalization197.63%
Interest Coverage-43.40
Cash Flow to Debt Ratio0.26
Company Equity Multiplier-1.36

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.85, provides a glimpse into top-line earnings distributed across each share. Net income per share, -6.45, reflects the portion of profit attributed to each share. The book value per share, -2.23, represents the net asset value distributed per share, while the tangible book value per share, -2.25, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.85
Net Income Per Share-6.45
Book Value Per Share-2.23
Tangible Book Value Per Share-2.25
Shareholders Equity Per Share-2.23
Interest Debt Per Share4.65

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 7.83%, indicates top-line expansion, while the gross profit growth, 7.82%, reveals profitability trends. EBIT growth, -16.50%, and operating income growth, -16.50%, offer insights into operational profitability progression. The net income growth, -672.50%, showcases bottom-line expansion, and the EPS growth, -670.80%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth7.83%
Gross Profit Growth7.82%
EBIT Growth-16.50%
Operating Income Growth-16.50%
Net Income Growth-672.50%
EPS Growth-670.80%
EPS Diluted Growth-786.17%
Weighted Average Shares Growth0.69%
Weighted Average Shares Diluted Growth-16.57%
Operating Cash Flow Growth-33.00%
Free Cash Flow Growth-33.06%
10-Year Revenue Growth per Share1342.19%
5-Year Revenue Growth per Share25.42%
3-Year Revenue Growth per Share16.58%
10-Year Operating CF Growth per Share150.01%
5-Year Operating CF Growth per Share354.11%
3-Year Operating CF Growth per Share11.43%
10-Year Net Income Growth per Share-173.82%
5-Year Net Income Growth per Share-248.54%
3-Year Net Income Growth per Share-1068.18%
10-Year Shareholders Equity Growth per Share-775.23%
5-Year Shareholders Equity Growth per Share-73.17%
3-Year Shareholders Equity Growth per Share-667.03%
Receivables Growth11.83%
Inventory Growth-100.00%
Asset Growth-57.20%
Book Value per Share Growth-152.72%
Debt Growth72.04%
R&D Expense Growth124.58%
SGA Expenses Growth14.41%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,401,560,400, captures the company's total value, considering both debt and equity. Income quality, -0.18, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 0.78%, indicates the value of non-physical assets, and capex to operating cash flow, -0.15%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value2,401,560,400
Income Quality-0.18
Research and Development to Revenue22.45%
Intangibles to Total Assets0.78%
Capex to Operating Cash Flow-0.15%
Capex to Revenue-0.06%
Capex to Depreciation-17.33%
Stock-Based Compensation to Revenue7.23%
Graham Number17.98
Return on Tangible Assets-214.43%
Graham Net Net-4.04
Working Capital-42,813,000
Tangible Asset Value-349,977,000
Net Current Asset Value-584,080,000
Invested Capital-2
Average Receivables122,290,000
Average Payables4,156,500
Average Inventory625,000.5
Days Sales Outstanding106
Days Payables Outstanding1815
ROIC64.12%
ROE2.89%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -3.04, and the price to book ratio, -3.04, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.42, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 5.85, and price to operating cash flows, 5.73, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-3.04
Price to Book Ratio-3.04
Price to Sales Ratio2.42
Price Cash Flow Ratio5.73
Price Earnings to Growth Ratio0.10
Enterprise Value Multiple-0.50
Price Fair Value-3.04
Price to Operating Cash Flow Ratio5.73
Price to Free Cash Flows Ratio5.85
Price to Tangible Book Ratio-5.13
Enterprise Value to Sales5.42
Enterprise Value Over EBITDA11.40
EV to Operating Cash Flow13.09
Earnings Yield-56.36%
Free Cash Flow Yield10.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Ironwood Pharmaceuticals, Inc. (IRWD) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.049 in 2024.

What is the ticker symbol of Ironwood Pharmaceuticals, Inc. stock?

The ticker symbol of Ironwood Pharmaceuticals, Inc. stock is IRWD.

What is company IPO date?

IPO date of Ironwood Pharmaceuticals, Inc. is 2010-02-03.

What is company current share price?

Current share price is 6.740 USD.

What is stock market cap today?

The market cap of stock today is 1071370180.000.

What is PEG ratio in 2024?

The current 0.103 is 0.103 in 2024.

What is the number of employees in 2024?

In 2024 the company has 267.